Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects

Research Communications in Molecular Pathology and Pharmacology

Volumn 103, Issue 2, 1999, Pages 211-222

  Courtois, P ^a   Sener, A ^a   Herbaut, C ^a   Turc, A ^a   Malaisse, W J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLIQUIDONE;

ADULT; AGED; AGING; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL;

AGED; FEMALE; GLICLAZIDE; GLIPIZIDE; GLYBURIDE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 0032817134     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Asmol, A.C. and Marble, A. (1984). Oral hypoglycaemic agents. An update. Drugs 28: 62-78.
2. Bergmeyer, H.U., Berndt, E., Schmidt, F. and Stork, H. (1974). Determination with hexokinase and glucose-6-phosphate dehydrogenase. In: Methods of Enzymatic Analysis Edited by Bergmeyer, H.U. Academic Press. New York. Pp. 1196-1201.
3. Ferner, R.E. and Chaplin, S. (1987). The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin. Pharmacokinetics 12: 379-401.
4. Fuccella, L.M., Tamassia, V. and Valzelli, G. (1973). Metabolism and kinetics of the hypoglycemic agent glipizide in man - comparison with glibenclamide. J. Clin. Pharmacol. 13: 68-75.
5. Gerich, J.E. (1989). Oral hypoglycemic agents. N. Engl. J. Med. 321: 1231-1245.
6. Helqvist, S., Hartling, S.G., Faber, O.K., Launchbury, P., Wåhlin-Boll, E. and Melander, A. (1991). Pharmacokinetics and effects of glipizide in healthy volunteers. Drug Invest. 3: 69-75.
7. Holmes, B., Heel, R.C., Brogden, R.N., Speight, T.M. and Avery, G.S. (1984). Gliclazide. A prelimnary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs 27: 301-327.
8. Jönsson, A., Rydberg, T., Ekberg, G., Hallengren, B. and Melander, A. (1994). Slow elimination of glyburide in NIDDM subjects. Diabetes Care 17: 142-145.
9. Kaubisch, N., Koss, F.W. and Hammer, R. (1980). The biochemistry of Glurenorm®. In: New Developments in the Oral Therapy of Diabetes Mellilus Edited by Pieterse, H. and Klarenbeek, K.G. Boehringer Ingelheim. Pp. 37-50.
10. Kobayashi, K.A., Bauer, L.A., Horn, J.R., Opheim, K., Wood Jr, F. and Kradjan, W.A. (1988). Glipizide pharmacokinetics in yound and elderly volunteers. Clin. Pharmacy 7: 224-228.
11. Koss, F.W., Kopitar, Z. and Hammer, R. (1976). Farmakokinetski profil Glurenorma, Diab. Croat. 5: 355-371.
12. Lebovitz, H.E. (1988). Oral hypoglycemic agents. Primary Care 15: 353-369.
13. Salive, M.E., Jones, C.A., Guralnik, J.M., Agodoa, L.Y., Pahor, M. and Wallace, R.B. (1995). Serum creatinine levels in older adults: relationship with health status and medications. Age and aging 24: 142-150.
14. 14-glipizide, a new antidiabetic. Diabetologia 9: 320-330.
15. Sener, A., Akkan, A.G. and Malaisse, W.J. (1995). Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma. Acta diabetol. 32: 64-68.
16. Wåhlin-Boll, E., Almér, L.-O. and Melander, A. (1982). Bioavailability, pharmacokinetics and effects of glipizide in type II diabetes. Clin. Pharmacokinetics. 7: 363-372.